Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In Re: Effexor XR Antitrust
Case Number:
15-1323
Court:
Nature of Suit:
Companies
Government Agencies
Sectors & Industries:
-
August 21, 2017
3rd Circ. Revives Lipitor, Effexor Antitrust Claims
The Third Circuit on Monday handed a sweeping victory to buyers of cholesterol drug Lipitor and antidepressant drug Effexor XR, reviving their antitrust claims for alleged patent fraud and anti-competitive reverse payment schemes.
-
May 18, 2017
3rd Circ. Could Up Ante For Buyers In Pay-For-Delay Cases
The Third Circuit will hear oral arguments Friday in a pair of pay-for-delay cases over the drugs Lipitor and Effexor that could heighten the standard needed to allege that agreements to settle pharmaceutical patent dispute litigation constitute so-called reverse payments that run afoul of antitrust law.
-
April 13, 2017
3rd Circ. Will Decide Lipitor, Effexor Pay-For-Delay Suits
The Third Circuit on Thursday said it has jurisdiction to consider the merits of two appeals of lower court dismissals of alleged pay-for-delay litigation over the drugs Lipitor and Effexor XR, rejecting calls by the pharmaceutical companies involved in the cases to transfer them to the Federal Circuit.
-
September 27, 2016
Drugmakers Tell 3rd Circ. To Punt Effexor To Fed. Circ.
Drugmakers Wyeth and Teva told the Third Circuit that purchasers’ claims of a reverse payment scheme over the generic version of the antidepressant Effexor XR belonged before the Federal Circuit, in the second case heard by the appeals court Tuesday on pay-for-delay jurisdictional issues.
-
April 06, 2015
Wyeth, Teva Push To Move Effexor Appeal To Fed. Circ.
Wyeth Inc. and Teva Pharmaceuticals USA Inc. on Thursday urged the Third Circuit to transfer an appeal in their pay-for-delay case over the antidepressant Effexor XR to the Federal Circuit, arguing that patent law is essential to the antitrust claims made by the drug purchasers, thereby justifying a transfer.